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ABSTRACT
DNA double-strand breaks (DSBs) are the most se-
vere type of DNA damage. DSBs are repaired by non-
homologous end-joining or homology directed repair
(HDR). Identifying novel small molecules that affect
HDR is of great importance both for research use and
therapy. Molecules that elevate HDR may improve
gene targeting whereas inhibiting molecules can be
used for chemotherapy, since some of the cancers
are more sensitive to repair impairment. Here, we per-
formed a high-throughput chemical screen for FDA
approved drugs, which affect HDR in cancer cells.
We found that HDR frequencies are increased by
retinoic acid and Idoxuridine and reduced by the an-
tihypertensive drug Spironolactone. We further re-
vealed that Spironolactone impairs Rad51 foci for-
mation, sensitizes cancer cells to DNA damaging
agents, to Poly (ADP-ribose) polymerase (PARP) in-
hibitors and cross-linking agents and inhibits tumor
growth in xenografts, in mice. This study suggests
Spironolactone as a new candidate for chemother-
apy.
INTRODUCTION
The most severe type of DNA damage is DNA double-
strand breaks (DSBs). Although our cells are constantly
challenged by DNA damage that is commonly repaired by
non-homologous end-joining (NHEJ), if not properly re-
paired, they can lead in some cases to complex chromoso-
mal translocations, cell death and cancer (1,2). Though the
last may be a rare event, cells harboring mutations, which
lead to uncontrolled cell cycle, have a selective advantage,
and thereforemight lead to tumors. Twomajor repairmech-
anisms have evolved to repair DSBs: NHEJ and homol-
ogous recombination (HR) based repair (3,4). NHEJ can
lead to an inaccurate repair as it may involve processing of
the DNA ends at the site of breakage. Homology directed
repair (HDR) is considered accurate, since it relies on the
sister chromatid as a template, and can therefore, mainly be
employed during or after S-phase of the cell cycle. During
HDR, DNA is processed to generate single-stranded ends
that are coated by Replication Protein A (RPA) and subse-
quently byRAD51 filaments. These nucleoprotein filaments
are then prone to invade the homologous strand so that sub-
sequent repair by HDR can take place (5,6,7).
In mammals, HDR occurs at a much lower frequency
than NHEJ (3,4,8,9,10,11,12,13,14,15,16). The rare occur-
rence of HDR may result in a less accurate DSB repair
and is probably the reason for low efficiency of gene target-
ing used in research and disease therapy. Deciphering the
molecular mechanism of HDR, including the components
it comprises and theirmodes of action, is key to understand-
ing how it can be potentially modulated for purposes of dis-
ease management and research.
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High-throughput screening approaches have been mostly
confined to searching for genes, which modulate HDR ef-
ficiency (17,18,19,20). Such screens are generally based on
siRNA techniques and often result in a relatively high false
positive rate due to non-specific silencing of genes, as was
recently demonstrated (18). Extending the search to iden-
tifying chemical compounds that modulate HDR would
be more applicable in a clinical setting, for example, to
decrease HDR prevalence in cancer chemotherapy or in-
crease HDR frequency to improve gene targeting efficiency.
Previous high-throughput screens for revealing chemical
components that modulate HDR have been limited to in-
vitro assays, by assessing Rad51 activity, Rad51 ability to
bind single-stranded DNA or RAD54 branch migration
(21,22,23,24,25).
Here, we developed a robust high-throughput screening
methodology with only negligible variance levels. We intro-
ducedDSBs in populations of cells with similar kinetics and
efficiency and screened for chemical compounds thatmodu-
late DSB repair by HDR. We identified and validated three
compounds that significantly affect HDR efficiency, two of
them Idoxuridine and retinoic acid (RA) augmented HDR,
while Spironolactone (Spiro) repressed HDR. We focused
on Spiro and found that in addition to inhibition ofHDR, it
sensitizes cells to radiomimetic drugs and PARP inhibitors
and cross-linking agents and it inhibits tumor growth in
xenografts in mice. We found that Spiro reduces RAD51
foci formation but does not act on resection. It should there-
fore be considered as potential chemotherapy agent, espe-
cially for patients who do not respond well to existing ther-
apy.
MATERIALS AND METHODS
Cell culture
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS),
except for U2OS-DRGFP and HRind cells that were cul-
tured in Phenol red-free DMEM that lacks phenol red and
with charcoal treated FCS, L-glutamine 20 mM, penicillin
500 units/ml and streptomycin 0.5 mg/ml (Biological In-
dustries, Beit Haemek, Israel) at 37oC and 5% CO2. U2OS-
DRGFP and HRind cells were maintained with 1 g/ml
puromycin or 0.2 mg/ml G418 and 1 mg/ml puromycin, re-
spectively.
Screen
Screening was performed at the High Throughput Screen-
ing facility of the Institut de Ge´ne´tique Et de Biolo-
gie Mole´culaire et Cellulaire, using the Prestwick Chemi-
cal Library R© (http://www.prestwickchemical.fr/) contain-
ing 1200 small molecules that are approved drugs. The
screen was performed in 96-well cell culture microplates
with a particular focus on avoiding microplate edge effects.
On day 1, 7500 HRind cells were seeded per 0.34 cm2 (96-
well) in 180l cell culturemedium (Phenol red-freeDMEM
supplemented with 4.5 g/l glucose, charcoal-treated FCS
10%, 400 G418 Puromycine) in the presence of small
molecule compounds (20Mfinal concentration, Dimethyl
sulfoxide (DMSO) concentration of 0.2% v/v). Cells were
then incubated at 37◦C, 5%CO2. Four hours after cell seed-
ing, Triamcinolone Acetonide (TA, 10−7 M final concentra-
tion) was added to promote mCherry-ISceI-GRLBD nu-
clear translocation. Controls wereDMSO alone (0.2% v/v),
DNA-PKi, NU7026 (20M inDMSO 0.2% v/v) or ATMi,
Ku55933 (10 M in DMSO 0.2% v/v). On day 4 (two and
a half day after TA addition), cells were washed, fixed with
1.5% paraformaldehyde, permeabilized with 0.5%TritonX-
100, stained with 4’,6-diamidino-2-phenylindole (DAPI) (1
g/ml). The screens were performed in a TECAN robotic
station (for cell handling, treatment and staining) and to a
Caliper Twister II robotic arm coupling microplate stacks
to the INCell1000 analyzer microscope (GE LifeSciences).
Statistical analysis of the screen
The Multi Target Analyzer software (GE LifeScience) was
used for a four steps analysis based on the shape (form fac-
tor), size and intensity of nuclei fluorescent stain DAPI,
and on the intensity of nuclear mCherry staining to select
positive U2OS reporter cells having a well response to TA
treatment with nuclear translocation of the ISceI endonu-
clease fused to the glucocorticoid receptor ligand-binding
domain (GRLBD) and mCherry protein (mCherry-ISceI-
GRLBD). DAPI was first used to find nuclei correspond-
ing to individual units considered by the analysis software.
We then selected mCherry positive cells using a threshold of
Nuc/Cyto intensity for mCherry intensity signal.
Then, we analyzed the DAPI digital signal to exclude
dead cells and their potential non-specific signal in both
Green Fluorescent Protein (GFP) and mCherry channels.
This exclusion was performed first using the nuclei form
factor parameter (called  Nuc1/form factor  by keep-
ing cells for which this parameter is below 1.48. The 
Nuc1/form factor  parameter corresponds to the mean
nucleus roundness index, its value ranging from 1 to in-
finity, where 1 is a perfect circle ( Nuc1/form factor 
= perimeter2/(4*p*Area)). Then we excluded cells having
the Nuclear Intensity Coefficient of Variation (CV) param-
eter above 0.19. This parameter corresponds to the coef-
ficient of variation of the intensity of pixels over the pop-
ulation of pixels comprising the nuclear region, meaning
that we excluded cells undergoing the characteristic apop-
totic nuclei condensation. Finally, the GFP nuclear signal
was analyzed to determine the efficiency of HR as reported
by the DR-GFP IsceI construct. Following image analy-
sis, the RReportGenerator software was used to determine
control-based normalized HDR frequencies in treated and
selected cells (26). A hit was defined as activator or repressor
when its normalized value deviatedmore (for up-regulators)
or less (for down-regulators) than 4 SD from the control
DMSO- and TA-treated cells mean value.
HDR flow cytometry based assays
Activation of the HRind cells was done by addition of 10−7
MDex (Sigma, Aldrich) and of the U2OS-DRGFP cells by
ISceI infection, using adenovirus (provided by F. Graham),
similarly to (18). Analyzing GFP-positive cells out of the
mCherry-positive cells in flow cytometric analysis was per-
formed using FACSAria Cell-Sorting System (BectonDick-
inson), similarly to Sartori et al. (33). For each compound,
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the background was set in the absence of DSB induction
and reduced using the same gate. Sample analysis was done
in FlowJo program.
Cell-cycle analysis
Cells were incubated with the different compounds or
DMSO for 24 h and stained with 5 mg/ml Hoechst-33342
(Molecular Probes, Eugene, OR, USA) for 20 min. Fol-
lowing extraction, cells were analyzed using flow cytometry
(SORP LSRII analyzer) for DNA content (UV 355 nm, 60
mW laser) and mCherry (561 nm, 25 mW laser) using Cel-
lquest or FlowJo programs. Doublets were discriminated
as described (27). Gating was set for DMSO and the same
gate was used for all the treatments. For statistical analysis
a paired, two tailed T test was performed using the Prism
software (Graphpad, CA, USA).
Cell survival assays
For survival assays, U2OS cells were plated in 6-well plates
in triplicates (500 cells per well) and were subsequently
treated with Spiro (10 M) or DMSO for 24 h. The next
day the cells were treated with increasing concentrations
of either Phleomycin or the PARP inhibitors ABT888 and
KU0058684 orMitomycin C (MMC) or Cisplatin. The cells
were treated with Phleomycin and Cisplatin for 1 h, with
MMC for 16 h, and then they were released with the ad-
dition of fresh medium containing Spiro or DMSO. Con-
versely, in the case of PARP inhibitors the cells were treated
throughout the whole survival assay in medium contain-
ing the appropriate PARP inhibitor combined with Spiro or
DMSO. Subsequently, the cells were let to grow in colonies
for 10 days. After 10 days, the cells were washed with phos-
phate buffered saline, fixed with 4% Formaldehyde for 30
min and stained with Crystal Violet (0,1% w/v) for 1 h. The
number of colonies per well was measured using the ImageJ
software.
In vivo tumor growth assay
Experiments were approved by the Israeli Animal Care and
Use Committee (NS-13–13812–4). Mice were kept in Spe-
cific Pathogen free (SPF) approved facility. For xenograft-
ing, weaned Nod-SCID males aged 8 weeks were sedated
with Isoflurane. Using a 27G needle 106 cells suspended in
a total volume of 100 l growing media were injected sub-
cutaneously to each flank. Following tumor establishment,
mice were divided into two groups (three mice in each) and
treated at a double-blind procedure, with 25 g/g body
weight of Spiro orDMSO, three times per week. Tumor vol-
ume was measured concurrently using a caliper and tumor
volume was calculated using the modified ellipsoidal for-
mula. Mice were weighed to monitor any changes in body
mass and their general health examined throughout the du-
ration of the experiment.
Antibodies for immunofluorescence and western blots
For immunofluorescence, U2OS cells were grown on cover-
slips, the cells were incubated with DMSO or Spiro (40
M) for 24 h and then mock or Phleomycin (10 g/ml)-
treated for 1 h. For recovery the cells were grown for 2, 6
or 24 h in the presence of DMSO or Spiro (40 M). In
the case of U2OS lacO/ISceI/tet19 cells (U2OS 19), the
cells were co-transfected with the plasmid vectors mCher-
ryLacI and HA-ISceI or empty vector and were grown
in medium containing Spiro or DMSO for 24 h. Subse-
quently, the cells were fixed with 4% formaldehyde and
permeabilized with 0.5% Triton X 100. Antibodies used
are rabbit anti-53BP1 (Bethyl Laboratories), mouse anti-
phospho-Histone H2A.X (Ser139), clone JBW301 (Merck
Millipore), rabbit anti-RAD51 PC130 (Calbiochem), rab-
bit anti-BRCA1 sc642 (Santa Cruz), mouse anti-CtIP clone
14–1 (Active Motif) and mouse anti-RPA32 NB600–565
(Novus). For western blots, U2OS cells were lysed in
RIPA buffer, the protein content was quantified by Brad-
ford and the samples were analyzed by sodium dode-
cyl sulphate-polyacrylamide gel electrophoresis. Antibod-
ies used are rabbit anti-phospho-Histone H2A.X (Ser139)
ab2893 (Abcam), rabbit anti-H2A.X ab11175 (abcam), rab-
bit anti-phospho-RPA32 S4/8 A300–245 (Bethyl), mouse
anti-RPA32 NB600–565 (Novus) and mouse anti-alpha-
tubulin T9026 (Sigma).
D-loop assay
The effect of Spiro on the RAD51 strand exchange activ-
ity was measured using the D-loop assay (28,29). Human
RAD51 (0.3 M) was incubated with Spiro (at indicated
concentrations) in buffer containing 25 mM Tris-acetate
(pH 7.5), 1 mM ATP, 1 mM CaCl2, 100 g/ml BSA, 2
mM DTT, and 20 mM KCl (added with the protein stock)
and 2% v/v DMSO (added with Spiro) for 10 min at 37◦C.
Then 32P-labeled 90-mer ssDNA (oligo#90) (0.9 M, nt)
was added and the nucleoprotein filaments were formed for
15 min at 37◦C. D-loop formation was initiated by addition
of pUC19 supercoiled dsDNA (15 M, nt) and carried out
for 15 min at 37◦C. The DNA products were deproteinized
by treatment with 1 mg/ml proteinase K in stop mixture
containing 1% SDS, 6% glycerol and 0.01% bromophenol
blue for 15 min at 37◦C, and analyzed by electrophoresis
in a 1% agarose gel in 1XTAE buffer (40 mM Tris acetate,
pH 8.3 and 1 mM EDTA) at 5 V/cm for 1.5 h. The gels
were dried on DEAE-81 paper (Whatman) and quantified
using a Storm 840 PhosphorImager and ImageQuant 5.2
(GE Healthcare) (28,29).
RESULTS
To identify chemical compounds that alter HDR in hu-
man cancer cells, we performed a high-throughput screen of
the Prestwick library, which includes 1280 approved drugs
(FDA, EMEA and other agencies), using the direct repeat
green fluorescent protein (DR)-GFP cassette system that
enables detection of HDR (30). This recombination assay
relies on the DRGFP sequence, which contains two mu-
tated GFP genes oriented as direct repeats and separated by
a drug selection marker (30). The upstream (5′) GFP gene
(cassette I) carries a recognition site for the meganuclease
ISceI, a rare-cutting endonuclease that does not cleave sev-
eral eukaryotic genomes tested. The downstream (3′) GFP
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(cassette II) is inactivated by upstream and downstream
truncations, leaving only ∼502 bp of GFP (30). Expres-
sion of ISceI leads to formation of DSBs and GFP recon-
stitution is a marker of HDR efficiency. We used the HR
inducible (HRind) cells that we previously established (8),
in which ISceI-induced DSB within the DRGFP cassette is
rapidly inflicted upon the addition of an external ligand. In
this system, IsceI is stably expressed as a chimera protein
fused to mCherry and to Glucorocticoid Receptor ligand-
binding domain (mCherry-ISceI-GRLBD). The ligand in-
duces the translocation of the already expressed, fluores-
cently labeled, ISceI from the cytoplasm into the nucleus.
This multi-color ‘switch on’ inducible cell-system obviates
the need for transfections, greatly reducing cell-to-cell vari-
ability (Figure 1a) (8).
The HRind cells were plated in 96-well plates and incu-
bated with the different compounds in triplicates. A DSB
was induced at the DRGFP cassette using TA that induces
nuclear entry of mCherry-ISceI-GRLBD (Figure 1a and
(8)). Following 2.5 days of incubation, the cells were fixed,
stained with DAPI and subjected to an automated fluores-
cencemicroscopy to determine the fraction ofGFP-positive
cells (Figure 1b and c). False positive hits due to non-
specific signals or auto-fluorescence are a major caveat in
high-throughput screens. To overcome this, we developed
a protocol that allows focusing only on the cell popula-
tion of interest and therefore minimizes false positives (see
Materials and Methods). DAPI staining was used to deter-
mine nuclei segmentation and shift outliers according to the
size and form of the nuclei. To determine the cells in which
the endonuclease entered the nucleus and thus induced a
DSB, the ratio of nuclear to cytoplasmic mCherry (from
mCherry-ISceI-GRLBD) signal was measured, and only
cells in which the ratio was higher than 1.05 were consid-
ered. The nuclear GFP intensity in these cells was measured
and the ratio between the GFP-positive to GFP-negative
cells was determined (Figure 1b and c).
Each plate contained mock (DMSO), as well as control
compounds that are known to augment or reduce HDR,
Nu7026 and Ku55933, respectively. As expected, DMSO
did not affectHDR,whereasNu7026 andKu55933 elevated
and decreased HDR, respectively, with very small varia-
tion between replicates (Figure 2). The threshold for poten-
tial hits was 4 SD, since HDR frequencies are very low in
human cells (Figure 2a). The primary screen revealed four
compounds (RA, Idoxuridine, Acitretin and Isotretinoin)
that increased HDR and three compounds (Spiro, Arip-
iprazole and Hycanthone) that decreased HDR (Table S1).
Interestingly, out of the four compounds found to elevate
HDR, three have a similar chemical structure and belong to
the retinoid family (RA, Acitretin and Isotretinoin; Figure
2c, Supplementary Figure S1a) and, both Spiro, which was
found to decrease HDR, andMegesterol Acetate (MegAc),
which decreased HDR bymore than 3 SD, are steroids with
a similar structure (Figure 2c, Supplementary Table S1 and
Figure S1b).
Next, we validated the effect of the potential candidates
identified in our screen on HDR using flow cytometry.
We tested RA, Idoxuridine, Acitretin, Isotretinoin, Arip-
iprazole, MegAc and Spiro, which, reassuringly, all con-
firmed the results from our screen (Figure 3). In this ex-
periment, different compounds and DMSO were added to
HRind cells for an hour followed by a mock treatment
or incubation, for two and a half days, with the ligand
Dexamethasone (Dex), which induces DSB by translocat-
ing mCherry-ISceI-GRLBD into the nucleus. The ratio of
HDR events following incubation with the different com-
pounds or DMSO was measured (Figure 3a). While grow-
ing the HRind cells for flow cytometry analysis, which re-
quire plating the cells in a higher density compared to the
screen, Aripiprazole and Hycanthone were found to be
toxic (data not shown) and hence we excluded them from
further analyses. Notably, MegAc repeatedly had a 4-fold
higher background of HDR events in the absence of DSB
formation (∼4% GFP-positive cells; Figure 3a, MegAc),
suggesting that it affects the GR and thus the nuclear loca-
tion of the endonuclease. To exclude the possibility that the
effects seen for the chemical compounds analyzed were due
to theGR translocation to the nucleus (31,32), we examined
the HDR modulators using an assay, which is independent
of the GR. To this end, we infected U2OS-DRGFP cells,
which stably contain the DRGFP cassette (33), with an ade-
novirus expressing the ISceI endonuclease (a kind gift from
F. Graham (McMaster University, Canada)). As we spec-
ulated, the background level of MegAc dropped down to
∼0.5%, which is similar to the levels found in cells treated
with DMSO, suggesting that MegAc partially influence the
mCherry-ISceI-GRLBD chimera even in the absence of
inducer. MegAc effect on HDR was significantly reduced
(Figure 3b, MegAc), suggesting that it acts as an antagonist
in the experimental system (HRind cells) rather than hav-
ing an effect on HDR, and therefore we excluded it from
further analyses. Retinoids can activate the GR (34,35). In-
deed, when inducing the DSB with infection of ISceI, the
effects of the retinoids, Isotretinin and Acitretin, seen with
the HRind system, which is an inducible GR-based system,
were abolished (Figure 3a, and b), indicating that they are
also an artifact of the system. RA, despite being a retinoid,
still had an effect of ∼10% increase on HDR in the non-
GR system. Idoxuridine, a nucleoside analogue had an in-
creasing effect on HDR frequency of more than 10% fol-
lowing ISceI infection (Figure 3). Interestingly, Spiro, de-
spite being a steroid, had the most significant effect when
analyzed with a non-GR system, a decrease of more than
50% in HDR frequency (Figure 3). The usage of a non-GR
system confirmed that Spiro reduces while RA and Idox-
uridine increase HDR frequency. Moreover, dose-response
analysis, using either the HRind or the viral ISceI system,
revealed that all three compounds act in a dose-dependent
manner (Figure 3c). Notably, Spiro, at a high concentration,
almost withhold HDR of the ISceI-induced DSBs (Figure
3c, right) and the IC50 was calculated to 15.2 M (Supple-
mentary Figure S2a).
Next, we examined the effect of the three compounds that
passed the validation steps (RA, Spiro and Idoxuridine) on
cell cycle progression (Supplementary Figure S3). Idoxuri-
dine, RA and Spiro did not have a significant effect on cell
cycle progression (Supplementary Figure S3).
Cells that harbor defects in HDR are hypersensitive to
various chemotherapy drugs and PARP inhibitors (36,37).
Therefore, we hypothesized that Spiro would sensitize
human cancer cells to radiomimetic drugs and enhance
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Figure 1. Design of the high-throughput screen for compounds that modulate HR frequencies. (a) A schematic representation of the HRind system.
The HRind cells are U2OS cells with an integrated DRGFP cassette that constantly express mCherry-ISceI-GRLBD, which is localized exclusively in the
cytoplasm. Upon the addition of the ligand TA, mCherry-ISceI-GRLBD enters the nucleus, and the endonuclease induces a DSB at the DRGFP cassette.
Repair by HDR can result in GFP expression. (b) Illustration of the high-throughput screen for chemicals that modulate HDR. Cells were plated in 96-well
plates and incubated with different compounds, from the Prestwick library. Four hours after cell seeding, TA was added for the induction of a DSB at the
DRGFP cassette. The cells were fixed, stained with DAPI and subjected to an automated fluorescence microscopy after 2.5 days. In each well, a fraction
of the cells expresses GFP (green, the DSB was repaired by HDR) while most cells are red (no HDR repair). (c) High-throughput picture analysis of the
screen. The first step consisted of detecting the cell nucleus using the DAPI staining and by applying size and form limitations. Then the Analyzer software
(GE Healthcare) was used to draw a ring around the nucleus corresponding to a part of the cytoplasm. By comparing the mCherry intensity between the
cytoplasmic ring and the nuclear ring, the translocation of mCherry-ISceI-GRLBD from the cytoplasm to the nucleus was estimated for each cell. Then,
cells for which there was no mCherry translocation (segmented in red) were rejected. Cells, which responded to the TA treatment (segmented in green),
were selected for further analysis. For the selected cells, the nuclear GFP signal was measured.
PARPi-induced lethality. To test this possibility, we assessed
cell survival in U2OS cells treated with 10 M of Spiro
that was shown not to affect cell survival when added alone
(Supplementary Figure S2b) and with increasing concen-
trations of Phleomycin (Figure 4a). As expected, when in-
cubating the cells with Spiro in the presence of Phleomycin,
cells showed higher sensitivity, with a decrease in colony for-
mation (Figure 4a). Interestingly, combining PARPi with
Spiro also results in fewer colonies, as demonstrated with
two different PARP inhibitors (Figure 4b). SinceHR affects
mainly sensitivity in DNA cross-linking agents, we assessed
cell survival in cells treated with combination of Spiro and
Cisplatin andMMC. Indeed, as depicted in Figure 4c, Spiro
addition increased the cell sensitivity of both cross-linking
agents (Figure 4c).
Spiro, an FDA approved drug, reduced DSB repair by
HDR (Figures 2 and 3) and inhibited cell survival and
colony formation of cancer cells in culture (Figure 4a, b,
c and Supplementary Figure 2b). Next, we wanted to test
whether it can also inhibit tumor growth in vivo. To this
end, NOD-SCIDmice aged 4–8 weeks were subcutaneously
injected with 106 HeLa cells suspended in a total volume
of 100 l growing media to each flank. After tumor estab-
lishment, mice were treated with Spiro (25 g per g body
weight) or DMSO, three times per week (double blind).
Tumors were measured three times per week. The tumor
growth of mice treated with Spiro was significantly reduced,
with some of the tumors totally obliterated, demonstrating
that Spiro may act to inhibit tumor growth in vivo (Figure
4d).
To get more insights into the mechanism that leads to
the impairment of HR, we asked whether DNA repair pro-
teins involved in HR are properly recruited at DSBs in cells
treated with Spiro. To tackle this question, we used a cellu-
lar system in which a single DSB can be created at a specific
genomic site. This system consists of an array composed of
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Figure 2. Compounds that modulate HDR frequencies. (a) HDR frequencies obtained from the 1280 compounds and controls (DMSO), a compound
that augments HDR (Nu7026) and a compound that reduces HDR (Ku55933). Each dot represents the average of three replicas (three different plates),
which each included 12 fields. The compounds are shown in alphabetical order, while repeats of the controls, which were found in each plate (DMSO in
orange, Nu7026 in green and Ku55933 in red), are scattered. The broken black and red lines indicate 3 SD and 4 SD, respectively, from the mean of HDR
frequency achieved with controls (DMSO). Indicated in blue are the three validated compounds (Idoxuridine, RA and Spiro). (b) Representative images
taken by the automatic screening platform. The different compounds, in which the cells were incubated, are indicated. (c) Quantification of the HDR events
for potential candidates. HDR frequencies of controls and the compounds which obtained 4 SD in the screen and were verified by observing their images
are shown.
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Figure 3. Validation demonstrating that Spiro, RA and Idoxuridine modulate HDR. (a, b) Flow cytometry images of cells that were incubated with the
indicated compounds and were either mock treated or induced for DSB formation at the DRGFP cassette. Top: representative images of flow cytometry
experiments, the percentage indicates GFP-positive cells in the gates. Bottom: quantification of at least three flow cytometry experiments. The relative HDR
intensity was calculated relatively to the control (DMSO; bottom). (a) HRind cells incubated with EtOh (Mock) or with Dex (Dex) for DSB induction.
(b) U2OS-DRGFP cells that do not stably express ISceI, infected (+ISceI) or not (−ISceI) with adenovirus expressing ISceI. (c) Dose-response curves for
validated HDR modulators. Left: HRind cells were incubated with the indicated compounds and concentrations and the fraction of GFP-positive cells
was determined as in Figure 1. Shown are average and SEM of three repeats. Right: U2OS-DRGFP cells were infected with an adenovirus that expresses
ISceI were incubated with different Spiro concentrations and the fraction of GFP-positive cells was determined as in (b).
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Figure 4. Spironolactone affects cell survival and inhibits tumor growth in mice. (a) Clonogenic survival of U2OS cells treated with the Spiro (10 M),
exposed to increasing concentrations of Phleomycin. SD represent the errors from three triplicates of the depicted experiment. (b) and (c) As in (a),
Survival assays of U2OS cells treated with the Spiro (10 M), exposed to increasing concentrations of PARP inhibitors ABT888 and KU0058684, MMC
or Cisplatin. (d). HeLa cells were injected into Nod-SCID (1 million HeLa cells suspended in a total volume of 100 l growing media to each flank). After
tumor establishment, mice were treated with Spiro (25 g per g body weight) or DMSO, three times per week. Tumors were measured three times per week.
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256 repeats of the lac operator (LacO) flanked by an ISceI
restriction enzyme site stable integrated in U2OS cells. Vi-
sualization of the break is achieved by the expression of lac
repressor (LacI) fused to GFP and expression of ISceI in-
duces a DSB that is exemplified by the early DNA damage
response (DDR) marker H2AX (Figure 5a, and (38)). In-
terestingly, the recruitment of BRCA1 and more particu-
larly RAD51 at the LacO array upon DNA damage is im-
paired in cells treated with Spiro compared to cells treated
with DMSO (Figure 5b and Supplementary Figure S4b).
Similar decrease inRAD51 foci formation uponDNAdam-
age and in the presence of Spiro was observed when cells
were treated with Phleomycin (Figure 5c).
To investigate whether Spiro acts on RAD51 potential
to bind single-strand DNA and its strand exchange activ-
ity, we performed D-loop formation assay in vitro in the
presence of Spiro. Our results depicted in Supplementary
Figure 5 show that Spiro does not affect RAD51 activity
and filament formation in vitro. There results, together with
the results indicating less foci formation by RAD51 in the
presence of Spiro (Figure 5), suggest that Spiro affects the
loading of RAD51 in DSBs in cells. To get more insights
into the dynamics of the RAD51 focus formation, we per-
formed time course analysis and we checked the kinetics of
RAD51 foci formation in Phleomycin and ISceI induced
breaks. We find that in both cases foci formation is delayed
and never reaches the levels of the control (DMSO) (Figure
5c and Supplementary Figure S6). Moreover, when we fo-
cus on cells that have RAD51 foci in the Spiro treated cells
we find that the focus is less intense (Figure 5d). These re-
sults suggest that Spiro affects the loading and the retention
of RAD51 in vivo.
Spiro treatment did not have amajor effect on the protein
levels of RAD51 and BRCA1 (Supplementary Figure S4a).
Moreover, the impairment of the recruitment of RAD51 is
not due to a defect in DNA end resection. Indeed, the per-
centage of cells with CtIP, an activator of resection, at the
LacO upon DNA damage is similar in cells treated with
Spiro and DMSO (Supplementary Figure S4b). Interest-
ingly, when we assessed the levels of p-RPA byWestern Blot
(WB), we observed a significant increase in resection exem-
plified by increased p-RPA levels (Figure 6a). Similarly, cells
treated with Spiro showed increased and sustained levels of
H2AX (Figure 6a).Moreover, analyzing the effect of Spiro
on foci formation by H2AXand 53BP1 due to Phleomycin
treatment reveals an increased number of foci per cell in the
presence of Spiro (Figure 6b). The above results are indica-
tive of elevated DDR and unrepaired breaks under these
conditions.
Altogether, our results indicate that Spiro modulates
HDR by affecting the RAD51 foci formation at DSBs.
DISCUSSION
Radiation therapy and chemotherapy aims to cure can-
cer by eradicating tumor cells. Both induce a variety of
DNA lesions, including oxidative base damages, single-
strand breaks and DSBs, which affect the DNA integrity,
leading to cell death (39). The use of high-energy radiother-
apy and high dose chemotherapy risks the development of
side effects and the generation of secondary malignancies in
the surrounding normal tissues. A main challenge of radi-
ation therapy nowadays is to maximize specific tumor cell
killing and minimize the normal tissue side effects. Thus,
the discovery of compounds that confer radiosensitization
specifically in cancer cells is of major importance.
Here we have performed a chemical screen to iden-
tify compounds that alter HDR. We utilized a library
with compounds that are already used in clinic for treat-
ment of other diseases (http://www.prestwickchemical.com/
index.php?pa=26). The advantage of such a screen is that
the drugs have been tested in humans and the concentra-
tions that the drugs are toxic as well as their side effects
are widely known. It therefore obviates the long years of
testing novel drugs for safety and stability in the human
body, and the drug is ready for doctors’ perception. More-
over, this work provides a significant step in robust high-
throughput screens methodology by using an inducible sys-
tem, which takes an advantage of protein localization con-
trol and its live visualization using fluorescent proteins. The
provided list of FDAapproved smallmolecules, whichmod-
ulate HDR to different extents, will be of benefit for the ge-
nomic stability community, enabling to further study the
mechanisms behind the control of this important repair
pathway.
The observation that components of the HDR pathway
are mutated or aberrantly expressed in many tumors (36),
and the correlation between tumor radio-resistance and in-
creased HDR activity make this repair pathway an attrac-
tive therapeutic target. The development of small-molecule
inhibitors that can decrease HDR efficiency can be an im-
portant strategy to improve radio and chemotherapy treat-
ment of cancer.
Spiro is a synthetic, steroidal agent that acts predom-
inantly as a competitive antagonist of the aldosterone
(or mineralocorticoid) receptor (40). It acts by indirect
inhibition of sodium reabsorption through the epithelial
sodium channel and stimulation of potassium retention, be-
ing therefore classified among potassium-sparing diuretics
(41). Because of its non-selective binding to Mineralocor-
ticoid receptor it exerts antiandrogen and weak progesto-
gen properties, as well as some indirect estrogen and gluco-
corticoid effects (32). Spiro is primarily used as a diuretic
and antihypertensive, but also for inhibiting androgen ac-
tivity in the body (40). Here, we describe a novel effect of
Spiro on DNA repair by HDR. We also demonstrate that
Spiro confers synthetic lethality to radiomimetic drugs and
PARP inhibitors and cross-linking agents such as MMC
and Cisplatin in cancer cells and inhibits tumor growth in
xenografts in mice. Our results suggest Spiro as a new can-
didate for chemotherapy.
Studies that aimed to investigate whether exposure to
Spiro affects the risk of incident breast cancer in women
over 55 years of age showed that the long-termmanagement
of cardiovascular conditions with Spiro does not increase
the risk of breast cancer in women older than 55 years with
no history of the disease (42). These results suggest that
Spiro action is specific in cancer cells and does not affect
normal cells.
During the recent years, several labs have performed
chemical screens and identified compounds that inhibit
RAD51 filament formation or activity in purified biochem-
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Figure 5. Spironolactone impairs recruitment of HDR related factors. (a) Schematic representation of the LacO/ISceI system. (b) Quantification of
RAD51 recruitment on the LacO array after treatment with Spiro. U2OS cells were co-transfected with mCherryLacI and HA-ISceI or empty vector and
treated at the same time with Spiro (40 M). After 24 h, cells were fixed and stained for RAD51. The number of co-localization and RAD51 foci with the
lacO array were counted in 100 cells. SD represent the errors from three independent experiments. Statistical significance was calculated using the t-test (*p
< 0.05, **p < 0.01, ***p < 0.001). (c) Spiro affects the kinetics of RAD51 foci formation. U2OS cells were treated with Spiro (40 M) or DMSO for 24
h followed by treatment of Phleomycin for 1 h and release for 2, 6 and 24 h in medium containing Spiro or DMSO. The cells were subsequently fixed and
stained with the RAD51 antibody. The number of foci positive cells (>3) was measured for each time point after analyzing 100 cells for each condition.
SD represent the errors from two independent experiments. (d) Spiro affects RAD51 foci intensity. U2OS 19 cells were treated as in (b) and finally were
fixed and stained with antibodies against RAD51 and RPA. Photos of 100 cells were obtained at a confocal microscope and the focus area intensity was
quantified for RAD51 (green) and RPA (cy5) using the Fiji software. The ratio between RAD51 focus intensity to the RPA focus intensity is depicted in
the right panel graph. Statistical significance was calculated using the t-test ( **p < 0.01, ***p < 0.001).
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Figure 6. Spironolactone treatment leads to persistent DNA damage. (a) U2OS cells were treated with Spiro (40 M) or DMSO for 24 h followed by
treatment of Phleomycin for 1 h and harvested after 0, 2, 6 or 24 h after this treatment. Cells were lyzed in RIPA buffer and analyzed by western blot
against the proteins RPA, H2AX and their phosphorylated versions (S4/8 for RPA and S139 for H2AX). Tubulin was used as a loading control. (b) Left:
U2OS cells were treated with Spiro or DMSO for 1 h, Phleomycin-treated for 1 h and left for recover for 6 h in the presence of Spiro or DMSO. Next, the
cells were fixed and co-stained for 53BP1, H2AX and DAPI. On the right, quantification of foci formation by H2AX (top) and by 53BP1 (bottom) from
two different immunofluorescence experiments. Cells were divided into subgroups according to the amount of foci (0–5, 6–20 or >20) per cell. Statistical
significance was calculated using the one tailed heteroscedastic t-test (*p < 0.05).
ical systems (21,22,23,24). Two of these compounds (B02
and RI-1) were also shown to sensitize cells to DNA dam-
aging agents and PARP inhibitors. In these studies, the com-
pounds were not tested in animal tumor models or tumor
xenografts making difficult to conclude whether they could
be potent in a clinical setting. Our data show that Spiro
treatment in mice xenografts derived from HeLa cells in-
jected subcutaneous decreased the development of the tu-
mor pointing to its potential as a chemotherapy agent. Al-
though we have focused in this study on Spiro, the screen
also identified two compounds that augment HDR effi-
ciency; these molecules may be utilized in gene targeting.
The three chemical compounds that we identified as modi-
fiers of HDR may act at different stages of the HDR path-
way. This is a benefit of our screen methodology that is
based on the HRind system, which relies on in vivo HDR
events and not on in vitro studies focused on one HR factor.
Revealing the mode of action of the different compounds
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during HDR is important for our understanding of this re-
pair pathway.
Reported chemicals that affect HR via inhibition of
RAD51 activity or filament formation (21,22,23,24) are all
aromatic molecules while Spiro is a steroid suggesting dif-
ferent modes of action of these compounds on RAD51 foci
formation. Indeed, our in vitro assays show no effect of
Spiro in D-loop formation. On the other hand, Spiro af-
fects RAD51 foci formation in cells, suggesting that loading
or retention of RAD51 at the sites of damage is impaired.
Spiro reducesHDRby affecting theRAD51 foci formation,
yet HDR may be affected at different steps of the HDR
pathway. The discovery that Spiro does not directly affect
the activity of RAD51 (at least in vitro) highlights the power
of the screen we have implemented, which scored for novel
compounds that alter HDR in cells and can affect different
components in this process. This is in contrast to being lim-
ited directed to examine activities of specific proteins, there-
fore missing compounds that affect other, even unknown
compounds of the HDR machinery. Therefore, beyond the
discovery of Spiro as a putative drug for chemotherapy, we
provide a resource for chemicals that alter HDR to differ-
ent extents and hope it will serve the community in shedding
light on the DDR.
Although further testing in xenografts, using different cell
types other thanHeLa, as well as in a variety of solid tumors
will be necessary to evaluate the full potential of Spiro as
chemotherapeutic agent, this work presents an important
step towards the development of new drugs in cancer ther-
apy.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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